AxoGen (AXGN) Receives Daily Media Impact Rating of 0.20

News coverage about AxoGen (NASDAQ:AXGN) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AxoGen earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 45.5611959038792 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of AxoGen (NASDAQ AXGN) opened at $28.00 on Tuesday. The company has a current ratio of 3.55, a quick ratio of 2.95 and a debt-to-equity ratio of 1.93. AxoGen has a fifty-two week low of $8.75 and a fifty-two week high of $31.70. The stock has a market capitalization of $954.63, a PE ratio of -70.00 and a beta of 0.40.

AxoGen (NASDAQ:AXGN) last issued its earnings results on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.06). AxoGen had a negative return on equity of 91.00% and a negative net margin of 24.74%. The business had revenue of $16.05 million during the quarter, compared to analysts’ expectations of $15.55 million. The company’s revenue was up 43.2% compared to the same quarter last year. research analysts expect that AxoGen will post -0.31 earnings per share for the current fiscal year.

AXGN has been the subject of several recent analyst reports. Leerink Swann lifted their price target on AxoGen from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Tuesday, November 21st. Lake Street Capital lifted their price target on AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 21st. Wedbush restated a “buy” rating and issued a $27.00 price target (up previously from $22.00) on shares of AxoGen in a report on Tuesday, November 21st. BidaskClub cut AxoGen from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 11th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of AxoGen in a report on Friday, January 5th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. AxoGen has an average rating of “Buy” and a consensus target price of $29.33.

In related news, Director Guido J. Neels sold 1,150,000 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $19.74, for a total transaction of $22,701,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jamie Mark Grooms sold 21,290 shares of the business’s stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $26.22, for a total value of $558,223.80. The disclosure for this sale can be found here. Insiders have sold a total of 1,293,990 shares of company stock valued at $26,494,898 in the last quarter. Company insiders own 9.33% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “AxoGen (AXGN) Receives Daily Media Impact Rating of 0.20” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/16/axogen-axgn-receives-daily-media-impact-rating-of-0-20.html.

About AxoGen

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Insider Buying and Selling by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply